Navigation Links
Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
Date:5/9/2013

SEATTLE, May 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013, for gross proceeds of $16.2 million. The shares were offered and are expected to be sold to RA Capital Management and other investors in a registered direct offering conducted without an underwriter or placement agent. The net proceeds from the offering, after deducting estimated offering expenses, will be approximately $16.1 million. The offering is expected to close on or about May 14, 2013.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for research and development expenses, such as funding planned clinical trials for its OMS103HP, PDE10, MASP-2 and PDE7 programs. The net proceeds may also be used to fund pre-clinical studies, capital expenditures, working capital and to otherwise advance Omeros' potential products towards commercialization.

The securities were offered by means of a prospectus supplement dated May 9, 2013 and accompanying prospectus dated October 18, 2010, forming a part of the Company's effective shelf registration statement (File No. 333-169856). Omeros has filed a registration statement (including a prospectus) with the Securities and Exchange Commission, or SEC, for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents Omeros has filed with the SEC for more complete information about Omeros and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, Omeros will arrange to send you the prospectus if you request it by calling Omeros at 206-676-5000. 

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding Omeros' expectations regarding the offering announced today and the use of proceeds thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

Contact:
Jennifer Cook Williams
+1-360-668-3701
jennifer@cwcomm.org


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
2. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
3. Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
4. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
5. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
6. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
7. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
8. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
9. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
10. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
11. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... --> --> This press release is ... --> Japan .  --> A separate press release has ... Shire continues to strengthen its presence ... Shire continues to strengthen its presence in ... continues to strengthen its presence in ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through ... Dermatology Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. ... the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company ...
(Date:2/11/2016)... Diego, CA (PRWEB) , ... February 11, 2016 , ... ... which was held in San Diego, CA, on February 6th & 7th, 2016 according ... combine for those who were not invited to the NFL’s combine in Indianapolis,” says ...
(Date:2/11/2016)... ... 11, 2016 , ... The book, “Computers Should Just Work!”, provides a basic, ... your IT consultant before signing a contract and how to spot an incompetent or ... relying heavily on e-mail and technology, it’s more important than ever to make sure ...
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of ... Round Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian ... Billy Cundiff. , “We are honored to support a promising young investigator from Dr. ...
(Date:2/10/2016)... Culver City, California (PRWEB) , ... February 10, ... ... Molecular Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will ... The theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will ...
Breaking Medicine News(10 mins):